---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027706"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:28:14.911830+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports Q4 net loss $19.2M; KOMET-001 trial hits primary endpoint; NDA plan Q2 2025

## Summary
- Q4 collaboration revenue $53.9M (from Kyowa Kirin), R&D $52.3M, net loss $19.2M vs $42.8M YoY.
- KOMET-001 achieved primary endpoint with 20-30% CR/CRh rate in R/R NPM1-mutant AML; NDA submission expected Q2 2025.
- FDA and EMA aligned on KOMET-017 Phase 3 protocol using MRD-negative CR for potential accelerated U.S. approval; topline 2028.
- Cash, equivalents and short-term investments $727.4M as of Dec 31, 2024; sufficient into 2027 with Kyowa funding.
- KOMET-007 Phase 1: 91% CR in 1L adverse-risk AML cohort with intensive chemo (7+3) combination.

## SEC filing metadata
- accession: 0000950170-25-027706
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/0000950170-25-027706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027706
- JSON: https://secwatch.observer/filing/0000950170-25-027706.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.